Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07253688 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Study acronym: RIFA-SNAP
StatusTerminated
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: After reviewing the recruitment to date as well as considering the anticipated ongoing recruitment challenges and feasibility, the decision was made to close the study. Show 6 more changesShow less
    • Final enrollment: 1 participants — under 1% of the 330 planned
    • Primary completion date changed from estimate of Dec 2029 to Sep 14, 2026
    • Eligibility criteria expanded, about 15 words
    • Site details revised
    • Collaborators: details revised at 1 of 4 entries
    • Publications: details revised at 2 of 2 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2025 to Nov 10, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Trial Details
NCT Number NCT07253688
Lead Sponsor Todd C. Lee MD MPH FIDSA
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR), University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Conditions
(from sponsor)		 Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov